CADL Profile
Candel Therapeutics, Inc., a clinical-stage biopharmaceutical company based in Needham, Massachusetts, is focused on advancing innovative immunotherapies for the treatment of various types of cancer. Established in 2003 and rebranded from Advantagene, Inc. to Candel Therapeutics, Inc. in November 2020, the company is at the forefront of developing cutting-edge viral-based therapies that aim to improve outcomes for cancer patients.
Candel's lead therapeutic candidate, CAN-2409, is a genetically engineered herpes simplex virus (HSV) that is currently undergoing multiple clinical trials. CAN-2409 is in Phase II clinical trials for pancreatic cancer, Phase III for prostate cancer, and Phase II for lung cancer, demonstrating its broad applicability across different cancer types. Additionally, CAN-2409 has completed Phase Ib/II trials for high-grade glioma, showcasing its potential in treating difficult-to-target tumors within the brain.
The company is also advancing CAN-3110, another HSV-based therapeutic agent that is in Phase I clinical trials for recurrent glioblastoma. This therapy aims to address the urgent need for effective treatments for this highly aggressive and often resistant brain cancer. Candel's approach with CAN-3110 represents a promising development in immunotherapy for glioblastoma, a cancer with limited treatment options.
Beyond its current pipeline, Candel Therapeutics is developing the enLIGHTEN Discovery Platform, a sophisticated HSV-based technology designed to leverage human biology and advanced analytics to create novel viral immunotherapies for solid tumors. This platform embodies the company's commitment to harnessing innovative technologies to advance cancer treatment. With a strong focus on expanding its therapeutic pipeline and improving patient outcomes, Candel Therapeutics continues to drive forward with its mission to revolutionize cancer care through cutting-edge immunotherapy solutions.
|
